Q2 EPS Forecast for Neumora Therapeutics Raised by Analyst

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Investment analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for Neumora Therapeutics in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.42) for the quarter, up from their prior estimate of ($0.43). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($1.68) EPS, FY2027 earnings at ($1.84) EPS, FY2028 earnings at ($1.51) EPS and FY2029 earnings at ($0.20) EPS.

A number of other equities analysts have also commented on the company. Stifel Nicolaus lowered Neumora Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the stock from $6.00 to $2.00 in a research note on Friday. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday. Guggenheim lowered Neumora Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday. Bank of America cut their price objective on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a research note on Wednesday, January 15th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Neumora Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

Neumora Therapeutics Price Performance

Neumora Therapeutics stock opened at $1.49 on Thursday. The stock’s 50 day moving average is $2.44 and its 200 day moving average is $8.64. The firm has a market cap of $240.73 million, a P/E ratio of -0.80 and a beta of 2.59. Neumora Therapeutics has a one year low of $1.30 and a one year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.

Institutional Investors Weigh In On Neumora Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its holdings in Neumora Therapeutics by 2.6% in the third quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock worth $851,000 after purchasing an additional 1,629 shares in the last quarter. SkyOak Wealth LLC increased its holdings in Neumora Therapeutics by 33.3% in the fourth quarter. SkyOak Wealth LLC now owns 20,000 shares of the company’s stock worth $212,000 after purchasing an additional 5,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Neumora Therapeutics during the fourth quarter valued at approximately $61,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Neumora Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 704,154 shares of the company’s stock valued at $7,464,000 after acquiring an additional 5,899 shares in the last quarter. Finally, PNC Financial Services Group Inc. bought a new stake in shares of Neumora Therapeutics during the fourth quarter valued at approximately $64,000. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.